Cytokinetics, Incorporated (CYTK)

Market Cap	5.40B
Revenue (ttm)	3.22M
Net Income (ttm)	-576.40M
Shares Out	118.01M
EPS (ttm)	-5.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	915,083
Open	47.29
Previous Close	46.99
Day's Range	45.51 - 47.42
52-Week Range	44.49 - 84.92
Beta	0.82
Analysts	Buy
Price Target	83.64 (+82.86%)
Earnings Date	Feb 25, 2025

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company’s drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Pha...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2023, Cytokinetics's revenue was $7.53 million, a decrease of -92.04% compared to the previous year's $94.59 million. Losses were -$526.24 million, 35.3% more than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $83.64, which is an increase of 82.86% from the latest price.

Price Target

$83.64

(82.86% upside)

Analyst Consensus: Buy